ea0070aep122 | Bone and Calcium | ECE2020
Kamenický Peter
, Javaid Kassim
, Keen Richard
, Lachmann Robin
, Ralston Stuart
, Cohen-Solal Martine
, Brandi Maria
, Briot Karine
, Crowley Rachel
, Walsh Jennifer
, Kolta Sami
, Rylands Angela
, Sun Wei
, Nixon Annabel
Introduction: Burosumab, a fully human monoclonal antibody to fibroblast growth factor 23 (FGF23), is the only approved treatment for XLH, a rare genetic disorder characterized by renal phosphate wasting and substantial cumulative musculoskeletal morbidity. BUR02 (NCT03920072) is a European phase 3b open-label study monitoring the long-term safety and efficacy of burosumab in adults with XLH from sites who participated in the CL303/CL304 studies (NCT02526160/02537431).<p c...